Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4, Randomized, Double-masked, Placebo-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of TEPEZZA® in Treating Patients With Chronic (Inactive) Thyroid Eye Disease

NCT04583735 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT04583735
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04583735 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4, Randomized, Double-masked, Placebo-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of TEPEZZA® in Treating Patients With Chronic (Inactive) Thyroid Eye Disease
Lead sponsor
Amgen
Phase
Phase 4
Overall status
Completed
Start date
September 2, 2021
Completion date
October 12, 2023
Enrollment
62 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

chronic (inactive) thyroid eye disease, thyroid eye disease